Pharma Marketing Network

MAY 12, 2021

Billion by 2026 with a CAGR of 37.2% The COVID-19 pandemic seriously accelerated the adoption and implementation of telehealth services, like remote patient monitoring and out-of-office “visits” – a trend that was already on the incline. And what are the implications to patients and providers? over the Forecast Period.”.

Physicians 59

Physicians Patients Safety Marketing 59

pharmaphorum

JULY 26, 2022

Merck’s exit came after other companies including Pfizer, Eli Lilly and Roche all scrapped CETP development programmes following safety or efficacy issues. BROADWAY and BOOKLYN will generate data in 2024, with PREVAIL set to read to in 2026, and if the results are positive will be followed by filings in the US, Europe, China and Japan.

Side effects 52

Side effects Safety Pharma Patients 52

pharmaphorum

OCTOBER 17, 2022

There are around 31,000 patients with ALS in the US. It remains to be seen whether the data from VALOR will convince the regulator to grant conditional approval while it waits for results from a confirmatory phase 3 trial (ATLAS ) in SOD1-ALS, which is due to generate results in 2026.

FDA 52

FDA Prospecting Competition Safety 52

Infuse Medical

JULY 4, 2024

Brief Overview of the Importance of Medical Device Maintenance Medical device maintenance ensures patient safety, operational efficiency, and regulatory compliance in healthcare settings. Regular maintenance helps prevent device malfunctions that could lead to incorrect diagnoses, treatment delays, or patient harm.

Training 52

Training Medical Healthcare Healthcare 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. starting new lung cancer patients on LIBTAYO® or melanoma patients on Opdualag instead of KEYTRUDA®).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

FEBRUARY 7, 2023

In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. Edward helps clients with compliance and safety issues, including in the development, launch and marketing of new products. of the MDR and Article 110.4

Medical 117

Medical Government Marketing Medicine 117

pharmaphorum

DECEMBER 21, 2022

The deal doesn’t include the follow-up to a prostate-specific membrane antigen (PSMA) directed prostate cancer therapy that was abandoned last year after two patient deaths linked to neurotoxicity, which will be spun out along with another solid tumour programme targeting prostate stem cell antigen (PSCA).

Pharma 52

Pharma Manufacturing Engineering Safety 52

Clarivate

AUGUST 27, 2024

In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. Abbott’s Volt should join the party in early 2026. Companies of interest in this regard include Atricure Inc., Pulse Biosciences Inc., Adagio Medical Inc., Acutus Medical Inc., Cardiofocus Inc.

Marketing 52

Marketing Competition FDA Electronics 52

Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D.

Marketing 52

Marketing Physicians Leads Sales 52

Pharmaceutical Technology

JANUARY 31, 2023

While insulin price caps will begin this year, larger effects will be delayed until 2026 – when the US federal government will be allowed to negotiate Medicare prices and demand rebates from drug companies that price gouge. That leaves three years for pharma companies to prepare.

FDA 52

FDA Prescription Medicine Biopharma 52

pharmaphorum

OCTOBER 27, 2022

Under the legislation, which has been slammed by pharma industry groups, Medicare pricing negotiations for some high-cost drugs would get underway in 2026, with drugmakers forced to pay rebates if prices rise faster than inflation.

Government 52

Government Insurance Safety Manufacturing 52

Pharmaceutical Technology

MAY 25, 2023

In part A, patients with metastatic/advanced tumours receive single agent, intra-tumoral administrations of BT-001. According to the companies report, the BT-001 single agent treatment was completed in 18 patients and no safety concerns were reported. The Phase I is divided into two parts.

Safety 52

Safety Patients Prospecting Marketing 52